Clinical Trial Update: Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) [Phase 3]

View source ↗

Summary

The document describes an ongoing Phase 3 clinical trial evaluating Sepofarsen for Leber congenital amaurosis (LCA) type 10, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Congenital Amaurosis

Drugs mentioned

• Sepofarsen (sepofarsen)

Snippet

Sponsor: Laboratoires Thea | Conditions: Leber Congenital Amaurosis 10, Blindness | Phase 3 | Status: RECRUITING